CervoMed (CRVO) Accounts Payables (2010 - 2026)
CervoMed (CRVO) posted Accounts Payables of $2.3 million for Q1 2026, up 56.28% sequentially from $1.5 million in Q4 2025, and up 22.14% YoY from $1.9 million in Q1 2025.
CervoMed (CRVO) Accounts Payables (2010 - 2026) Analysis & Trends
CervoMed has reported Accounts Payables for 17 years, with the latest figure at $2.3 million in Q1 2026.
- Quarterly Accounts Payables rose 22.14% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 22.14% YoY) and the FY2025 annual result came in at $1.5 million, down 3.79% from the prior year.
- Accounts Payables rose to $2.3 million in Q1 2026 per CRVO's latest filing, from $1.5 million in the prior quarter.
- Over five years, Accounts Payables peaked at $2.3 million in Q1 2026 and troughed at $97302.0 in Q4 2022.
- A 5-year average of $1.1 million and a median of $932427.0 in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables plunged 89.73% in 2022, then surged 580.84% in 2023.
- Over 5 years, Accounts Payables stood at $97302.0 in 2022, then soared by 580.84% to $662471.0 in 2023, then jumped by 128.15% to $1.5 million in 2024, then dropped by 3.79% to $1.5 million in 2025, then soared by 56.28% to $2.3 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $2.3 million, $1.5 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - | 687,111.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 687,111.00 |
| Mar 31, 2026 | 2.27 Mn |
| Dec 31, 2025 | 1.45 Mn |
| Sep 30, 2025 | 1.35 Mn |
| Jun 30, 2025 | 1.85 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Dec 31, 2024 | 1.51 Mn |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 725,854.00 |
| Mar 31, 2024 | 679,739.00 |
| Dec 31, 2023 | 662,471.00 |
| Sep 30, 2023 | 533,790.00 |
| Jun 30, 2023 | 932,427.00 |
| Mar 31, 2023 | 971,455.00 |
| Dec 31, 2022 | 97,302.00 |
| Sep 30, 2022 | 807,372.00 |
| Jun 30, 2022 | 846,032.00 |
| Mar 31, 2022 | 813,197.00 |
| Dec 31, 2021 | 947,495.00 |
| Sep 30, 2021 | 678,036.00 |